T1014 Acid Inhibition on First and Seventh Days of Administering Two Different Proton Pump Inhibitors in Japanese Patients: Randomized Two-Way Crossover Study

remission (CDAI <150) was assessed at intervals throughout the study. For this analysis, patients were followed through 2 years of treatment (1 year in CHARM and up to 1 additional year in ADHERE). Results: Of 75 patients who received blinded adalimumab weekly during CHARM and were in remission upon entry to ADHERE, 64 (85%) maintained reduced dosing frequency of adalimumab (40 mg eow) during ADHERE. Of these 64 patients, clinical remission was maintained in 54 (84%) and 50 (78%) at Weeks 92 and 116, respectively. Conclusion: In this study, long-term clinical remission of Crohn's disease was maintained in a high percentage of patients after a reduction of adalimumab dosing frequency from 40 mg weekly to 40 mg eow.